CorMedix Inc. (CRMD) shares surged 12.60% in Wednesday's intraday trading session following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year guidance. The biopharma company's performance significantly exceeded analyst expectations, driven by strong sales of its flagship product, DefenCath.

CorMedix reported a third-quarter earnings per share (EPS) of $1.26, substantially beating the analyst consensus estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. The company's robust performance was largely attributed to DefenCath sales, which contributed $88.8 million to the quarter's net revenue of $104.3 million.

In light of the strong quarterly performance, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 million to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to between $220 million and $240 million. This optimistic outlook, coupled with the strong Q3 results, has fueled investor enthusiasm, leading to the significant stock price jump. The company's successful integration of Melinta Therapeutics, which is reportedly ahead of schedule and capturing synergies of approximately $30 million, further bolsters its growth prospects in the biopharmaceutical sector.